FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367721088> ?p ?o ?g. }

• W4367721088 abstract "<h3>Background and Importance</h3> Isavuconazol has a safety profile and favorable pharmacokinetic characteristics. However, studies in real-life practice have found unexpected drug levels in different groups of patients. <h3>Aim and Objectives</h3> To develop a population pharmacokinetic model (PopPK) that describes the behaviour of isavuconazole in prophylaxis and treatment of invasive fungal infections (IFI) and to evaluate possible factors affecting dosage. <h3>Material and Methods</h3> A prospective, multidisciplinary study including immunosuppressed patients treated with oral and intravenous isavuconazole as prophylaxis or treatment for IFI was carried out from June 2020 to January 2022. Variables considered were: demographic, clinical, biochemical and genetic (polymorphisms, presence of inductors, inhibitors and the degree of saturation -DG- of drug-metabolising enzymes of CYP3A4, CYP3A5 and CYP2B6). DG was tested using SuperCYPsPred. <h3>Blood samples were collected predose</h3> Isavuconazole was analysed using ultra performance liquid chromatography coupled with ultraviolet detection. Non-linear mixed effects modelling using first-order conditional estimation with interaction (FOCEI) was used to develop the PopPK model using NONMEM v7.4. Data visualisation and statistical analyses were carried out in R v.3.4. <h3>Results</h3> A total of 31 patients (10 females) from the haematology (19) and intensive care (12) services were included in the study. The median (interquartile range) age was 58 (17) years and total body weight was 77 (17) kg. The percentage of patients who presented non-wild type genotypic was 20% for CYP3A4. 99 samples were determined and the mean concentration (standard desviation) was 1.80 (0.95) µg/mL. Isavuconazole PK was best described by a single-compartment model with first order absorption and elimination. Isavuconazole absorption rate was fixed at 22.6 1/h as previously reported by Cojutti et al. 2021. The apparent volume of distribution was 147 L and the apparent clearance (CL/F) was described by the following equation: CL/F(L/h)=3.54*(ALB/2.9)^-0.7*(BS/1,9)^1,9*(1+0.8)^3A4ind where serum albumin (ALB) is expressed in g/dL; body surface (BS) in m² and 3A4ind indicates the presence of inductor drugs for CYP3A4. The interindividual variability for CL/F was 40% and the residual variability was 30% (additive) and 0,05 µg/mL (proportional). <h3>Conclusion and Relevance</h3> The developed PopPK model adequately characterises the kinetic behaviour of isavuconazole and includes the ALB, BS and the presence of inductors of CYP3A4 parameters that affect its clearance. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest" @default.
• W4367721088 created "2023-05-04" @default.
• W4367721088 creator A5001783697 @default.
• W4367721088 creator A5018426498 @default.
• W4367721088 creator A5021080924 @default.
• W4367721088 creator A5029369436 @default.
• W4367721088 creator A5043882196 @default.
• W4367721088 creator A5047657559 @default.
• W4367721088 creator A5080949963 @default.
• W4367721088 creator A5086080025 @default.
• W4367721088 creator A5088604271 @default.
• W4367721088 creator A5089616529 @default.
• W4367721088 date "2023-03-01" @default.
• W4367721088 modified "2023-10-16" @default.
• W4367721088 title "4CPS-239 Population pharmacokinetics of isavuconazole based on phamacogenetics in immunosuppressed patients" @default.
• W4367721088 doi "https://doi.org/10.1136/ejhpharm-2023-eahp.427" @default.
• W4367721088 hasPublicationYear "2023" @default.
• W4367721088 type Work @default.
• W4367721088 citedByCount "0" @default.
• W4367721088 crossrefType "proceedings-article" @default.
• W4367721088 hasAuthorship W4367721088A5001783697 @default.
• W4367721088 hasAuthorship W4367721088A5018426498 @default.
• W4367721088 hasAuthorship W4367721088A5021080924 @default.
• W4367721088 hasAuthorship W4367721088A5029369436 @default.
• W4367721088 hasAuthorship W4367721088A5043882196 @default.
• W4367721088 hasAuthorship W4367721088A5047657559 @default.
• W4367721088 hasAuthorship W4367721088A5080949963 @default.
• W4367721088 hasAuthorship W4367721088A5086080025 @default.
• W4367721088 hasAuthorship W4367721088A5088604271 @default.
• W4367721088 hasAuthorship W4367721088A5089616529 @default.
• W4367721088 hasBestOaLocation W43677210881 @default.
• W4367721088 hasConcept C112705442 @default.
• W4367721088 hasConcept C126322002 @default.
• W4367721088 hasConcept C2776239304 @default.
• W4367721088 hasConcept C2908647359 @default.
• W4367721088 hasConcept C71924100 @default.
• W4367721088 hasConcept C99454951 @default.
• W4367721088 hasConceptScore W4367721088C112705442 @default.
• W4367721088 hasConceptScore W4367721088C126322002 @default.
• W4367721088 hasConceptScore W4367721088C2776239304 @default.
• W4367721088 hasConceptScore W4367721088C2908647359 @default.
• W4367721088 hasConceptScore W4367721088C71924100 @default.
• W4367721088 hasConceptScore W4367721088C99454951 @default.
• W4367721088 hasLocation W43677210881 @default.
• W4367721088 hasOpenAccess W4367721088 @default.
• W4367721088 hasPrimaryLocation W43677210881 @default.
• W4367721088 hasRelatedWork W10390674 @default.
• W4367721088 hasRelatedWork W1459641852 @default.
• W4367721088 hasRelatedWork W2009939288 @default.
• W4367721088 hasRelatedWork W2039830992 @default.
• W4367721088 hasRelatedWork W2070015783 @default.
• W4367721088 hasRelatedWork W2087821742 @default.
• W4367721088 hasRelatedWork W2104998353 @default.
• W4367721088 hasRelatedWork W2142247990 @default.
• W4367721088 hasRelatedWork W2391487123 @default.
• W4367721088 hasRelatedWork W2504642767 @default.
• W4367721088 isParatext "false" @default.
• W4367721088 isRetracted "false" @default.
• W4367721088 workType "article" @default.